Helixmith Co Ltd
KOSDAQ:084990
Helixmith Co Ltd
Inventory
Helixmith Co Ltd
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Helixmith Co Ltd
KOSDAQ:084990
|
Inventory
₩871.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
4%
|
|
|
Celltrion Inc
KRX:068270
|
Inventory
₩2.7T
|
CAGR 3-Years
62%
|
CAGR 5-Years
47%
|
CAGR 10-Years
27%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Inventory
₩211.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Inventory
₩6.7B
|
CAGR 3-Years
49%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Helixmith Co Ltd
Glance View
Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-29. The firm operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
See Also
What is Helixmith Co Ltd's Inventory?
Inventory
871.5m
KRW
Based on the financial report for Sep 30, 2025, Helixmith Co Ltd's Inventory amounts to 871.5m KRW.
What is Helixmith Co Ltd's Inventory growth rate?
Inventory CAGR 10Y
4%
Over the last year, the Inventory growth was 16%. The average annual Inventory growth rates for Helixmith Co Ltd have been -2% over the past three years , -24% over the past five years , and 4% over the past ten years .
